Open Access<p>Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration</p>
Author(s) -
Jianxin Chen,
Junhui Wang,
Xilin Wu
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s262594
Subject(s) - t790m , medicine , osimertinib , epidermal growth factor receptor , lung cancer , cancer research , adenocarcinoma , tyrosine kinase , cancer , pharmacology , oncology , gefitinib , receptor , erlotinib
Epidermal growth factor receptor (EGFR) in trans-C797S alteration has been considered as one of the mechanisms, which leads to the resistance to third-generation tyrosine kinase inhibitors (TKI). Several reports have suggested that combination therapy with first- and third-generation TKIs might be effective for acquired trans-C797S alteration.